ASCO 2015 | Dose adherence and baseline exposure analysis of ibrutinib for relapsed/refractory CLL

Jacqueline Barrientos

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukemia (CLL) from the phase 3 RESONATE trial.

Share this video